Other groups have examined FLT3-ITD expression in AML and although it has been found to be associated with AML progression from MDS and a worse outcome in patients with AML in general (Pollard et al. 2006; Shih et al. 2004), this is still a matter for debate in APL. This evidence concerns the gene FLT3 and acute myeloid leukemia.